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Background
Recently, we have started a clinical trial to treat patients
with high risk acute leukaemia with a donor-derived
HA-1-TCR transduced virus-specific T-cell product as
early as 8 weeks and 14 weeks after allogeneic stem cell
transplantation (allo-SCT). Donor derived Cytomegalo-
virus (CMV)- and Epstein Bar virus (EBV)-specific
T-cells will be isolated using Streptamer based Clini-
MACS selection, and will be subsequently transduced at
day 2 with the well-characterized anti-leukaemic HA-1-
TCR and infused 10-12 days later. Based on these well-
defined specificities this T-cell product is predicted to
result in a selective Graft versus Leukaemia (GvL) effect
without Graft versus Host Disease (GvHD). Important
study parameters are persistence of the T-cell product,
feasibility of generation of HA-1-TCR transduced virus-
specific T-cells, and the number of events of acute GvHD.
Material and methods
To obtain therapeutic cell numbers, one of the inclusion
criteria is presence in donor peripheral blood of 1 or 2
virus-specific T-cell population with a frequency of
≥0.05% of T-cells. MHC-Streptamers will be used to iso-
late 1 or 2 virus-specific T-cell populations from donor
leukocytes. MHC-Streptamer incubation will result in
binding of the TCR of the virus-specific T-cells of inter-
est to the specific peptide presented by the MHC mole-
cule on the Streptamers. Next to allowing selection of
T-cells of interest, this binding will also result in specific
stimulation allowing subsequent transduction with the
HA-1-TCR. The process of isolation of pure populations
of virus-specific T-cells and transduction with good
manufacturing practice (GMP)-grade retroviral superna-
tant encoding the HA-1-TCR has been validated with 4
large scale test procedures in the cleanroom. To pass the
in process (IP) testing, T-cells needed to be ≥50% pure
for the respective virus-specific tetramer directly after
Streptamer isolation. In addition, after transduction and
subsequent culturing T-cells need to be ≥60% antigen-
specific, as measured with virus- and HA-1-tetramers.
Moreover, transduction efficiency of ≥5% as measured
with HA-1-tetramers is a prerequisite.
Results
All HA-1-TCR td virus-specific T-cell products met the
criteria for IP testing and quality control testing. They
contained >90% antigen-specific T-cells and >10% HA-1
tetramer positive T-cells. Moreover, all HA-1-TCR td
virus-specific T-cell products were highly reactive
against HA-1-positive leukaemic cells.
Conclusions
Here, we present a GMP-grade procedure to generate in
a short culture period of less than 2 weeks therapeuti-
cally relevant numbers of defined antigen-specific and
highly anti-leukaemia reactive T-cells.
Authors’ details
1Leiden University Medical Center, Hematology, Leiden, the Netherlands.
2Leiden University Medical Center, Clinical Pharmacy and Toxicology, Leiden,
the Netherlands.
1Leiden University Medical Center, Hematology, Leiden, the Netherlands
Full list of author information is available at the end of the article
van Loenen et al. Journal for ImmunoTherapy of Cancer 2014, 2(Suppl 2):P48
http://www.immunotherapyofcancer.org/content/2/S2/P48
© 2014 van Loenen et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Published: 12 March 2014
doi:10.1186/2051-1426-2-S2-P48
Cite this article as: van Loenen et al.: P74. A Good Manufacturing
Practice procedure to generate therapeutic numbers of highly pure
anti-leukaemic virus-specific T-cells. Journal for ImmunoTherapy of Cancer
2014 2(Suppl 2):P48.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
van Loenen et al. Journal for ImmunoTherapy of Cancer 2014, 2(Suppl 2):P48
http://www.immunotherapyofcancer.org/content/2/S2/P48
Page 2 of 2
